Intro Summary: Your antibody–drug conjugate program is walking a tightrope between power and buildability; the ADC CDMO you choose is the safety net—or the wind gust. Ten decisions separate clean, on-schedule INDs from costly do-overs, each tied to capabilities a world-class ADC & Bioconjugate CDMO must show: precise drug placement (site-specific conjugation), true OEB-5 HPAPI […]